Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Commercial Officer

Chief People Officer

Chief Medical Officer

General Counsel & Secretary

Chief Development Officer

Chief Executive Officer

Chief Financial Officer

Chief Accounting Officer

Chief Operating Officer

Chief Scientific Officer

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare di...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2024-02-16	Premium	sold	Premium	Premium	Premium	Chief People Officer
2024-02-16	Premium	acquired	Premium	Premium	Premium	Chief People Officer
2024-02-05	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief People Officer
2024-02-02	Premium	acquired	Premium	Premium	Premium	Chief People Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	General Counsel & Secretary
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Development Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief People Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Accounting Officer
2024-01-08	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief People Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Development Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Accounting Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	General Counsel & Secretary
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2024-01-05	Premium	sold (taxes)	Premium	Premium	Premium	Chief Commercial Officer

SWTX - SpringWorks Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SWTX